RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $82
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $81 to $82.
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $81 to $82.